Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Donald Trump to surrender to New York prosecutors on Tuesday
    • Vladimir Putin’s new doctrine calls US ‘main source’ of threat to Russian security
    • ‘Dare to fight’: Xi Jinping unveils China’s new world order
    • Pro-Trump protesters fail to show up in New York
    • Ron DeSantis falls in line with Republicans in closing ranks behind Donald Trump
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Mis-steps that brought Virgin Orbit crashing back to earth
      • UBS shortlists four consultants for Credit Suisse integration
      • EY bosses present united front after dispute over stalled break-up plan
      • New John Lewis boss tells employees business must change ‘at pace’
      • ThyssenKrupp revives sale of submarine and marine systems unit
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Prepare for a multipolar currency world
      • Nasdaq records best quarter since 2020 after volatile start to year
      • Bond markets are still skittish — but they have reason to be
      • Flood of cash into US money market funds could add to banking strains
      • UK is global equity markets ‘backwater’, Nick Train warns
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • Why are Americans dying so young?
      • We are living through a trillion-dollar rebalancing
      • Prepare for a multipolar currency world
      • The wheels of justice turn for a former US president
      • Bond markets are still skittish — but they have reason to be
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Boomerang chief executives provide comfort in times of crisis
      • Matthew Desmond: ‘America does so much more to subsidise affluence than alleviate poverty’
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Serhiy Prytula: ‘The defence minister said: “Try to buy a satellite.” I thought he was joking’
      • Homebuyers chase their European dreams despite economic outlook
      • I used AI to bet on horse-racing. Here’s what happened
      • Essay: Is being a perfectionist really a bad thing?
      • Hamnet reborn: a pandemic bestseller moves from page to stage
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Donato Paolo Mancini

    Pharmaceuticals correspondent

    Donato writes about the drug industry, Covid-19, and international organisations like the WHO. Previously, he worked for The Wall Street Journal and Dow Jones Newswires.
    Email Donato Paolo Mancini @donatopmancini  on Twitter (link opens in a new browser window)

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Tuesday, 28 March, 2023
      Coronavirus pandemic
      Gisaid data move boosts hopes of establishing Covid-19 origins

      Research will aid independent assessment of potential animal link to virus outbreak

    • Monday, 27 March, 2023
      BioNTech
      BioNTech forecasts slump in sales as demand for Covid jab wanes

      Expected fall highlights challenges for pharmaceutical companies that experienced pandemic windfall

    • Thursday, 23 March, 2023
      Disease control and prevention
      WHO warns over spread of Marburg virus after Tanzania deaths

      Global health body urges increased vigilance to reduce transmission of deadly disease

    • Friday, 17 March, 2023
      Coronavirus pandemic
      WHO urges China to share more data on possible Covid link to raccoon dogs

      Health body says genetic sequences are not definitive and all origin theories, including lab leak, remain on table

    • Tuesday, 14 March, 2023
      Covid-19 vaccines
      Pfizer’s revised EU Covid vaccine contract meets resistance

      Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots

    • Saturday, 11 March, 2023
      Coronavirus pandemic
      Vaccine inequality blamed for boosting global Covid death toll

      Unequal access to jabs in 2021 led to one preventable death every 24 seconds, politicians and activists say

    • Tuesday, 21 February, 2023
      Drug prices
      AbbVie accused of overcharging Dutch for flagship drug Humira

      Drugmaker taken to court by public interest group for abusing market position and profiteering

    • Tuesday, 21 February, 2023
      ExplainerMedical science
      How likely is a human bird flu pandemic?

      Scientists urge more vigorous action to reduce circulation of highly contagious H5N1 strain

    • Wednesday, 1 February, 2023
      GSK PLC
      GSK bullish on 2023 as earnings surpass expectations

      UK drugmaker’s shingles vaccine boosts sales while demand for Covid-related products falls

    • Tuesday, 24 January, 2023
      News in-depthDrug prices
      Big pharma groups rejoin battle with governments on drug prices

      Tight budgets and US reforms are ending a truce between the industry and health authorities

    • Monday, 9 January, 2023
      CureVac GmbH
      Covid vaccine makers CureVac and Novavax appoint new chiefs

      Pharmaceutical groups to part ways with longstanding executives

    • Thursday, 5 January, 2023
      ExplainerCoronavirus pandemic
      How serious is the threat of new Covid-19 variants?

      A surge in cases after China lifted restrictions has sparked concerns that a dangerous new strain could emerge

    • Wednesday, 4 January, 2023
      Coronavirus pandemic
      China has under-represented its number of Covid deaths, says WHO

      Global health body issues its strongest rebuke yet of Beijing’s handling of the pandemic

    • Wednesday, 21 December, 2022
      Coronavirus pandemic
      WHO urges China to step up vaccinations after rise in Covid cases

      Beijing asked to make more data available on disease severity, hospital admissions and occupancy rates

    • Wednesday, 21 December, 2022
      ExplainerAntibiotic resistance
      Surge in infections leads to global shortage of antibiotics

      Manufacturers struggle to keep pace with post-pandemic demand as dozens of countries report low supply of drugs

    • Monday, 14 November, 2022
      Roche Holding AG
      Roche late-stage Alzheimer’s trials end in failure

      Two studies of antibody treatment gantenerumab fail to slow decline in people with early-stage disease

    • Wednesday, 9 November, 2022
      Bavarian Nordic AS
      Bavarian Nordic boosted by monkeypox vaccine

      Price tag of between $70 and $300 a dose helps push Danish biotech to ‘all-time high revenues’

    • Wednesday, 2 November, 2022
      Drugs research
      Magic mushrooms study finds ‘significant’ effect on depression

      UK-led research paves way for regulatory approval of active ingredient psilocybin

    • Wednesday, 2 November, 2022
      US opioid epidemic
      US pharmacy groups CVS and Walgreens agree $10bn opioid settlements

      Other chains also in talks over claims linked to their roles in crisis

    • Wednesday, 2 November, 2022
      GSK PLC
      GSK lifts guidance after shingles vaccine boost

      UK drugmaker beats forecasts and ‘expects good momentum in 2023’

    • Tuesday, 1 November, 2022
      Johnson & Johnson Co Inc
      Johnson & Johnson bucks global M&A slowdown with $16.6bn Abiomed deal

      Purchase of heart pumpmaker to help US pharma group focus on drugs and medical devices

    • Thursday, 27 October, 2022
      Disease control and prevention
      Cases of drug-resistant tuberculosis rise for first time in almost 20 years

      WHO report highlights global resurgence of the disease during coronavirus pandemic

    • Monday, 24 October, 2022
      Special ReportFT Health: Communicable Diseases
      Monkeypox recedes as doctors draw lessons for future outbreaks

      Engagement with at-risk groups forms a vital part of any response

    • Monday, 10 October, 2022
      Covid-19 vaccines
      Oxford/AstraZeneca nasal Covid vaccine fails in trial

      Setback for a method hoped to provide better protection against virus transmission

    • Thursday, 6 October, 2022
      Coronavirus treatment
      Merck Covid antiviral pill did not cut hospitalisation risk, study finds

      UK trial shows ‘no difference’ between taking molnupiravir or placebo in reducing clinical admissions during Omicron wave

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In